Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.
Five things for pharma marketers to know: Monday, November 9, 2015
Obama administration tells states they cannot restrict hep-C drugs; AstraZeneca says it will acquire ZS Pharma: Allergan CEO says drug discovery is too risky
Novartis: Cardiologists slow to advocate on behalf of new drugs
Attention turns to Valeant, which is facing subpoenas from two attorneys general who are seeking information about the drugmaker’s patient-assistance, drug-pricing and drug-distribution practices.
The pharmacy benefit manager included both PCSK9 inhibitors on its national formulary. Spending on the drugs is estimated to reach $750 million in 2016.
Five things for pharma marketers to know: Tuesday, October 6
The FDA approves Opdivo/Yervoy combination to treat melanoma; BioMarin acquires global rights to Kuvan; Allergan’s Juvederm receives marketing approval for lip augmentation